BRAF and Ehlers-Danlos syndrome, musculocontractural type: However, effective therapeutic options for patients with wild-type BRAF are lacking.<h4>Case</h4>In our phase II study, patients having advanced/metastatic solid ATCs were treated with famitinib and camrelizumab, a combination therapy involving a multi-targeted kinase inhibitor and an anti-PD-1 antibody.